SK Bioscience Co Ltd Cash Flow-to-Debt Ratio
SK Bioscience Co Ltd cash flow-to-debt ratio. SK Bioscience Co Ltd (302440) has a Cash Flow-to-Debt Ratio of 0.02x as of September 2025, meaning its operating cash flow of ₩20.65 Billion could theoretically repay 0% of its total liabilities (₩847.96 Billion) in one year. Check SK Bioscience Co Ltd (302440) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of SK Bioscience Co Ltd (2018–2024)
Cash flow-to-debt ratio of SK Bioscience Co Ltd from 2018 to 2024. Historical debt coverage capacity for SK Bioscience Co Ltd across 7 annual periods. Check how high is SK Bioscience Co Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.
SK Bioscience Co Ltd Cash Flow-to-Debt Ratio by Year (2018–2024)
SK Bioscience Co Ltd cash flow-to-debt ratio by year from 2018 to 2024. Year-by-year debt coverage analysis for SK Bioscience Co Ltd. For the full cash flow conversion analysis, see SK Bioscience Co Ltd cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.16x | ₩-128.02 Billion | ₩821.14 Billion | ▼ -178.9% |
| 2023 | 0.20x | ₩29.35 Billion | ₩148.58 Billion | ▲ +163.3% |
| 2022 | -0.31x | ₩-124.96 Billion | ₩400.23 Billion | ▼ -129.6% |
| 2021 | 1.05x | ₩536.59 Billion | ₩508.81 Billion | ▲ +161.8% |
| 2020 | 0.40x | ₩120.22 Billion | ₩298.44 Billion | ▲ +216.1% |
| 2019 | 0.13x | ₩21.82 Billion | ₩171.25 Billion | ▲ +64.2% |
| 2018 | 0.08x | ₩14.90 Billion | ₩191.98 Billion | — |